Portola Pharmaceuticals prices upsized IPO at $14.50, within the range

By Renaissance Capital,

Shutterstock photo

Portola Pharmaceuticals, which is developing a blood thinner and a novel reversal agent for acutely ill patients, raised $122 million in an upsized IPO by offering 8.4 million shares at $14.50, the midpoint of the $13 to $16 range. Portola commands a market cap of $491 million. The company originally set terms for a deal that would have raised $100 million at the midpoint and valued the company at a market cap of $469 million.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: PTLA

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com